ArticleGene therapy1999
Insulation of a conditionally expressed transgene in an adenoviral vector.
Article in Gene therapy, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 76 citations in OpenAlex.
- Genomic Context and Insert Orientation in the Regulation of Transgene Expression in Adenoviral Vectors.International journal of molecular sciences · 2026Review
- Identification of oncolytic vaccinia restriction factors in canine high-grade mammary tumor cells using single-cell transcriptomics.PLoS pathogens · 2020Article
- Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.Journal of cancer research and clinical oncology · 2015Article
- Adenoviral insulinoma-associated protein 1 promoter-driven suicide gene therapy with enhanced selectivity for treatment of neuroendocrine cancers.Ochsner journal · 2013Article
- Modifications to the INSM1 promoter to preserve specificity and activity for use in adenoviral gene therapy of neuroendocrine carcinomas.Cancer gene therapy · 2012Article
- Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma.Journal of biomedical science · 2012Article
- Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.Cancer gene therapy · 2011Article
- Therapeutic potential of replication-selective oncolytic adenoviruses on cells from familial and sporadic desmoid tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
- Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.Journal of molecular medicine (Berlin, Germany) · 2008Review
- Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli.BMC biotechnology · 2006Article
- Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD.Cancer gene therapy · 2006Article
- The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context.Cancer gene therapy · 2006Article
- Optimization of radiation controlled gene expression by adenoviral vectors in vitro.Cancer gene therapy · 2005Article
- Article
- Transcription initiation activity of adenovirus left-end sequence in adenovirus vectors with e1 deleted.Journal of virology · 2003Article
- Tetracycline-inducible transgene expression mediated by a single AAV vector.Gene therapy · 2003Article
- Potential limitations of transcription terminators used as transgene insulators in adenoviral vectors.Gene therapy · 2002Article
- Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells.Cancer gene therapy · 2001Article
- Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters.Gene therapy · 2001Article
- Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment.Breast cancer research : BCR · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Replication-defective recombinant adenoviruses provide an efficient system for in vivo gene transfer and numerous studies have demonstrated that this vector can accommodate tissue-specific promoters to restrict the expression of a transgene to a particular subset of cells. However, in some cases the selectivity of expression is lost when the tissue-specific promoter is placed in an adenoviral environment. In an attempt to restore the conditionality of expression of the transgene driven by the human ERBB2 promoter, we have flanked the expression cassette in 5' and 3' orientations with a 250 bp sequence containing the bovine growth hormone transcriptional stop signal for cloning into a recombinant adenovirus. The data presented here clearly demonstrate that these 'insulator' elements are able to restrict the expression of the transgene (herpes simplex thymidine kinase) to ERBB2-expressing cells and therefore to restore the selectivity mediated by the ERBB2 promoter. This approach could be generally useful to insulate expression cassettes in adenoviral vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.